Detalhe da pesquisa
1.
Indolent lymphoma care delivery and outcomes during the COVID-19 pandemic in Ontario, Canada.
Br J Haematol
; 204(3): 805-814, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37886835
2.
Contact Days Associated With Cancer Treatments in the CCTG LY.12 Trial.
Oncologist
; 28(9): 799-803, 2023 09 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37226534
3.
In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program.
Haematologica
; 108(1): 196-206, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35734926
4.
Superior outcomes with paediatric protocols in adolescents and young adults with aggressive B-cell non-Hodgkin lymphoma.
Br J Haematol
; 196(3): 743-752, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34599525
5.
Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma.
Blood
; 136(23): 2628-2637, 2020 12 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32785666
6.
Risk stratification for relapsed/refractory classical Hodgkin lymphoma integrating pretransplant Deauville score and residual metabolic tumor volume.
Am J Hematol
; 97(5): 583-591, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35170780
7.
Clinical significance of clonal hematopoiesis in the setting of autologous stem cell transplantation for lymphoma.
Am J Hematol
; 97(12): 1538-1547, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36087071
8.
Validation of the RHL30 digital gene expression assay as a prognostic biomarker for relapsed Hodgkin lymphoma.
Br J Haematol
; 190(6): 864-868, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32510594
9.
Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma-type post-transplant lymphoproliferative disorder.
Br J Haematol
; 189(1): 97-105, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32068243
10.
Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2.
Cancer Immunol Immunother
; 68(5): 773-785, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30747243
11.
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.
Blood
; 130(16): 1800-1808, 2017 10 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-28774879
12.
Monolithic 3D printing of embeddable and highly stretchable strain sensors using conductive ionogels.
Nanotechnology
; 30(36): 364002, 2019 Sep 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31121565
13.
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
Lancet Oncol
; 19(2): 257-266, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29276022
14.
Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma.
Blood
; 128(2): 185-94, 2016 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-27166360
15.
Methotrexate, cytarabine, thiotepa and rituximab (MATRix) chemoimmunotherapy for primary central nervous system lymphoma: a Toronto experience.
Haematologica
; 108(4): 1186-1189, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36453110
16.
A bioclinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma.
Haematologica
; 103(2): 288-296, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29097500
17.
A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma.
Br J Haematol
; 178(3): 434-441, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28440559
18.
Nephrotic Syndrome With Cancer Immunotherapies: A Report of 2 Cases.
Am J Kidney Dis
; 70(4): 581-585, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28648302
19.
Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12.
Blood
; 126(6): 733-8, 2015 Aug 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26109202
20.
The positive effect of a dedicated adolescent and young adult fertility program on the rates of documentation of therapy-associated infertility risk and fertility preservation options.
Support Care Cancer
; 25(6): 1915-1922, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28155019